June 2011 in “Oncology times” New treatments are making advanced prostate cancer management more complex but also more hopeful.
Dutasteride reduces prostate cancer risk by 23% in high-risk men.
3 citations
,
September 2020 in “Bladder cancer” 5α-reductase inhibitors don't stop bladder cancer from developing or getting worse.
38 citations
,
January 2005 in “PubMed” Dutasteride effectively treats enlarged prostate with manageable side effects.
11 citations
,
June 2005 in “Postgraduate Medical Journal” Some infants temporarily grow scrotal hair, which usually disappears on its own without any health issues.
September 2010 in “European Urology Supplements” Higher urethral PSA levels after prostate removal surgery may be linked to more hair loss and higher PSA levels post-surgery.
April 2017 in “The journal of sexual medicine” 5-alpha-reductase inhibitors significantly affect the penile tissue of hypertensive rats.
1 citations
,
September 2023 in “Prostate International” Cervi Parvum Cornu complex improved urinary symptoms in men without major side effects.
March 2026 in “Panacea Journal of Medical Sciences” The technique successfully reconstructed a functional neo-vagina with 100% survival and patency, but lacked mucus secretion.
April 2017 in “Journal of Investigative Dermatology” Dermal lymphatic vessels help hair growth by affecting hair cycle phases.
September 2009 in “European Urology Supplements” Surgery for high-risk prostate cancer is challenging but doesn't lead to more complications, and additional treatment is often needed.
September 2004 in “Urology” Finasteride may reduce prostate cancer risk.
17 citations
,
May 2018 in “PeerJ” VB-1, a natural compound, may promote hair growth by enhancing a key cell growth pathway.
54 citations
,
November 2001 in “Urology” The length of the CAG repeat in the androgen receptor gene affects the risk and progression of prostate cancer, BPH, infertility, and undermasculinized genitalia.
1 citations
,
April 1999 in “The Journal of Urology”
March 2025 in “MAEDICA – a Journal of Clinical Medicine” COVID-19 may worsen symptoms of benign prostatic hyperplasia (BPH).
August 2009 in “Australian Prescriber” Dutasteride is approved to help manage prostate enlargement.
October 2022 in “Journal of health sciences and medicine” Middle-aged and elderly men with BPH had higher hospitalization rates for COVID-19.
34 citations
,
January 2000 in “Journal of Andrology” CAG repeat polymorphism and prostate zone volume are not reliable markers of long-term androgen sensitivity.
April 2013 in “The FASEB Journal” Dutasteride showed some prevention of prostate issues but also had limitations, especially with high-grade tumors.
21 citations
,
May 2021 in “Prostate Cancer and Prostatic Diseases” COVID-19 might worsen symptoms and progression of benign prostatic hyperplasia, possibly due to inflammation and metabolic disturbances in the prostate gland. More research is needed to confirm this.
10 citations
,
February 2019 in “Toxicological Sciences” Finasteride exposure affects gene expression and anogenital distance in male rat fetuses.
April 2012 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Early hair loss in men could be a sign of non-cancerous prostate enlargement, and treating hair loss early might help prevent prostate issues later.
April 2018 in “The Journal of Urology” Phosphodiesterase inhibitors like tadalafil can reduce cell growth in BPH caused by CD8+ T cells in low androgen conditions.
38 citations
,
October 2014 in “Current Opinion in Endocrinology, Diabetes and Obesity” 5-alpha reductase deficiency leads to male sexual development issues and treatments like finasteride help with prostate enlargement and hair loss.
March 2025 in “Laboratory Investigation” MESTSV is a rare tumor that is mostly benign but needs long-term monitoring due to potential recurrence.
April 2017 in “The Journal of Urology” Finasteride before TURP reduces blood loss and improves early postoperative quality of life.
Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.
2 citations
,
May 2019 in “PubMed” Oral finasteride and dutasteride may negatively affect erectile function in rats.
April 2012 in “The Journal of Urology” Male pattern baldness may predict prostate cancer risk.